Evaluating delay of gamma oscillations in patients with schizophrenia using evoked response audiometry system.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 07 2022
05 07 2022
Historique:
received:
15
03
2022
accepted:
22
06
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
8
7
2022
Statut:
epublish
Résumé
Impaired gamma oscillations found in a 40-Hz auditory steady-state response (ASSR) in patients with schizophrenia are the robust findings that can be used for future biomarker-based therapeutics. To apply these significant observations into the clinical practice, a clinical system for evoked response audiometry (ERA) may be available. In this study, the delayed 40-Hz ASSR, which was reported as a potent biomarker for schizophrenia, was examined using the ERA system in patients with schizophrenia and its clinical relevance was investigated. The phase of ASSR was significantly delayed in patients with schizophrenia compared with the healthy subjects. The delayed phase was associated with severity of the disease symptoms in the patients. A phase delay with aging was found in healthy subjects, but not in patients with schizophrenia. These findings show availability of the ERA system to identify the delayed 40-Hz ASSR and its clinical implication in patients with schizophrenia. Further applications of the ERA system in clinical psychiatry are warranted in developing biological assessments of schizophrenia with 40-Hz ASSR.
Identifiants
pubmed: 35790750
doi: 10.1038/s41598-022-15311-6
pii: 10.1038/s41598-022-15311-6
pmc: PMC9256618
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11327Informations de copyright
© 2022. The Author(s).
Références
Sci Rep. 2022 Jan 7;12(1):287
pubmed: 34997139
Nat Rev Neurosci. 2010 Feb;11(2):100-13
pubmed: 20087360
Arch Gen Psychiatry. 1999 Nov;56(11):1001-5
pubmed: 10565499
J Acoust Soc Am. 1991 Nov;90(5):2467-79
pubmed: 1774415
Biol Psychiatry. 2017 Jul 1;82(1):26-39
pubmed: 27817844
Am J Psychiatry. 2016 Apr 1;173(4):373-84
pubmed: 26651391
Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Feb;4(2):131-139
pubmed: 30314905
Acta Neurobiol Exp (Wars). 2013;73(4):564-70
pubmed: 24457646
Curr Opin Psychiatry. 2016 May;29(3):202-10
pubmed: 26900672
Biol Psychiatry. 2006 Dec 1;60(11):1231-40
pubmed: 16893524
Nat Rev Neurosci. 2005 Apr;6(4):312-24
pubmed: 15803162
Schizophr Res. 2021 Feb;228:280-287
pubmed: 33493776
Schizophr Bull. 2009 Nov;35(6):1065-77
pubmed: 19726534
Neuroimage Clin. 2019;23:101878
pubmed: 31228795
Schizophr Res. 1995 Oct;17(2):177-85
pubmed: 8562492
Neuroimage. 2008 Oct 1;42(4):1481-9
pubmed: 18634887
Biol Psychiatry. 2011 May 15;69(10):989-96
pubmed: 21216392
JAMA Psychiatry. 2016 Nov 01;73(11):1145-1153
pubmed: 27732692
Proc Natl Acad Sci U S A. 1981 Apr;78(4):2643-7
pubmed: 6941317
Neuropharmacology. 2012 Mar;62(3):1504-18
pubmed: 21349276
Arch Gen Psychiatry. 1967 Feb;16(2):146-51
pubmed: 6019329
Schizophr Res. 2018 Nov;201:278-286
pubmed: 29807805
Nat Rev Drug Discov. 2008 Jan;7(1):68-83
pubmed: 18064038
Ann N Y Acad Sci. 2015 May;1344:27-36
pubmed: 25809615
Brain Res. 2011 Sep 21;1413:98-114
pubmed: 21840506
Nat Med. 2006 Sep;12(9):1016-22
pubmed: 16960576
Am J Psychiatry. 2003 Dec;160(12):2238-40
pubmed: 14638599
Audiol Neurootol. 2001 Jan-Feb;6(1):12-27
pubmed: 11173772
Biol Psychiatry. 2008 Sep 1;64(5):369-75
pubmed: 18400208
Schizophr Bull. 2008 Sep;34(5):907-26
pubmed: 18684772
Schizophr Bull. 2008 Sep;34(5):927-43
pubmed: 18562344
JAMA Psychiatry. 2015 Aug;72(8):813-21
pubmed: 25587799
Biol Psychiatry. 2015 Jun 15;77(12):1010-9
pubmed: 25847179
Schizophr Res. 2012 Jun;138(1):1-7
pubmed: 22542616
Neuroimage. 2009 Oct 1;47(4):1711-9
pubmed: 19371786
BMC Neurosci. 2009 Jul 20;10:85
pubmed: 19619324
Curr Psychiatry Rep. 2013 Mar;15(3):346
pubmed: 23400808